PL2068899T3 - Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych - Google Patents

Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych

Info

Publication number
PL2068899T3
PL2068899T3 PL07838266T PL07838266T PL2068899T3 PL 2068899 T3 PL2068899 T3 PL 2068899T3 PL 07838266 T PL07838266 T PL 07838266T PL 07838266 T PL07838266 T PL 07838266T PL 2068899 T3 PL2068899 T3 PL 2068899T3
Authority
PL
Poland
Prior art keywords
incidence
duration
reducing
lactobacillus acidophilus
respiratory infections
Prior art date
Application number
PL07838266T
Other languages
English (en)
Inventor
Gregory Leyer
Arthur Ouwehand
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2068899(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Publication of PL2068899T3 publication Critical patent/PL2068899T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL07838266T 2006-10-02 2007-09-14 Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych PL2068899T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
EP07838266.0A EP2068899B1 (en) 2006-10-02 2007-09-14 Lactobacillus acidophilus for use in reducing the incidence and duration of respiratory infections
PCT/US2007/020033 WO2008042101A2 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing the incidence and duration of illness

Publications (1)

Publication Number Publication Date
PL2068899T3 true PL2068899T3 (pl) 2015-12-31

Family

ID=39268947

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14186663.2T PL2839836T5 (pl) 2006-10-02 2007-09-14 Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
PL07838266T PL2068899T3 (pl) 2006-10-02 2007-09-14 Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14186663.2T PL2839836T5 (pl) 2006-10-02 2007-09-14 Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego

Country Status (13)

Country Link
US (5) US20100040579A1 (pl)
EP (2) EP2068899B1 (pl)
JP (3) JP5896589B2 (pl)
KR (2) KR101485200B1 (pl)
CN (1) CN101528244B (pl)
AU (1) AU2007302715B2 (pl)
BR (1) BRPI0719787A2 (pl)
DK (2) DK2068899T3 (pl)
ES (2) ES2650375T5 (pl)
FI (1) FI2839836T4 (pl)
MX (1) MX2009003260A (pl)
PL (2) PL2839836T5 (pl)
WO (1) WO2008042101A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102668233B (zh) 2009-12-02 2015-01-28 株式会社Kmw 设备选择结构
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
EP2627198B1 (en) * 2010-10-15 2015-09-02 Chr. Hansen A/S Immunoadjuvant
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
ES2856013T3 (es) 2013-11-15 2021-09-27 Nestle Sa Composiciones para su uso en la prevención o tratamiento de infecciones del TRS en bebés o niños jóvenes en riesgo
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
PH12017550044B1 (en) 2015-03-05 2022-04-27 Socia‰Ta‰ Des Produits Nestla‰ S A Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
WO2020170981A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用処置具、内視鏡、フローラ治療法
EP4040984B1 (en) 2019-09-25 2026-02-18 Tall Goods, LLC Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
CA2271930C (en) * 1996-11-29 2006-10-17 Bio K + International Inc. Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
MXPA05003597A (es) 2002-10-11 2005-06-03 Wyeth Corp Formulaciones nutricionales que contienen sustancias simbioticas.
US20090257993A1 (en) * 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) † 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
EP2248430A3 (en) * 2005-02-15 2011-01-12 Barry R. Goldin A food containing a probiotic and an isolated beta-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
AU2006297895B2 (en) 2005-10-06 2011-09-01 Probi Ab Use of lactobacillus for treatment of virus infections

Also Published As

Publication number Publication date
EP2839836A1 (en) 2015-02-25
DK2839836T4 (da) 2024-08-26
JP2014058558A (ja) 2014-04-03
MX2009003260A (es) 2009-05-11
EP2068899A2 (en) 2009-06-17
KR20090063222A (ko) 2009-06-17
US20100040579A1 (en) 2010-02-18
EP2839836B1 (en) 2017-08-30
US20140356329A1 (en) 2014-12-04
ES2650375T3 (es) 2018-01-18
DK2068899T3 (da) 2015-09-28
CN101528244A (zh) 2009-09-09
BRPI0719787A2 (pt) 2014-11-25
AU2007302715A1 (en) 2008-04-10
PL2839836T3 (pl) 2018-02-28
KR101485200B1 (ko) 2015-01-26
CN101528244B (zh) 2012-01-11
US20230256037A1 (en) 2023-08-17
ES2650375T5 (en) 2025-02-03
KR20140002069A (ko) 2014-01-07
JP2010505824A (ja) 2010-02-25
WO2008042101A3 (en) 2009-04-09
PL2839836T5 (pl) 2025-11-17
US20200316145A1 (en) 2020-10-08
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
KR101474188B1 (ko) 2014-12-17
AU2007302715B2 (en) 2013-01-31
EP2068899B1 (en) 2015-07-01
US20180000875A1 (en) 2018-01-04
EP2839836B2 (en) 2024-06-26
DK2839836T3 (en) 2017-12-04
JP5896589B2 (ja) 2016-03-30
FI2839836T4 (fi) 2024-08-26
ES2547480T3 (es) 2015-10-06

Similar Documents

Publication Publication Date Title
PL2068899T3 (pl) Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych
ZA200905886B (en) Methods and kits for administering probiotics
EP2088980A4 (en) ELASTIC LAMINATE AND ABSORBENT ARTICLE COMPRISING THE LAMINATE
ZA200902486B (en) Carbon coated magnetic nanoparticles and their use in separation processes
GB2443823B (en) Devices and methods for use in construction
PT2162118T (pt) Microesferas porosas e sua utilização em terapia
EP2093049A4 (en) COMPOSITE SURFACES AND THE COMPOSITE SURFACE APPLICATION OF THE ABSORBENT ARTICLE
IL211041A0 (en) Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
IL211684A0 (en) Antibodies against human il 17 and uses thereof
IL200108A0 (en) Solid preparation comprising alogliptin and pioglitazone
PL2219658T3 (pl) Kompozycja oparta na bakteriach probiotycznych w połączeniu z prebiotykiem i jej zastosowanie w zapobieganiu i/lub leczeniu schorzeń oddechowych i/lub infekcji oraz do polepszenia funkcjonalności jelit
EP2222359A4 (en) DEVICES AND METHOD FOR TREATMENT OF BREATHING IN SLEEP
IL201018A0 (en) Novel asparaginases and uses thereof
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EG26285A (en) Absorbent and thin composite product
PL2087094T3 (pl) Lactobacillus fermentum ess-1, dsm17851 i jego zastosowanie do leczenia i/lub zapobiegania kandydozie i zakażeniom dróg moczowych
GB0722996D0 (en) Depsipeptides and their therapeutic use
PL2010828T3 (pl) Urządzenie do oczyszczania powietrza i mikrobiologicznego zabezpieczenia w zamkniętych środowiskach
PL2209527T3 (pl) Kompozycje farmaceutyczne zawierające probiotyki L.acidophilus i Bifidobacterium lactis do stosowania w leczeniu zaburzenia czynnościowego jelit
IL222333A0 (en) Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP1853284A4 (en) USE OF LACTOBACILLUS KEFIRANOFACIENS AS PROBIOTIC AND SYNBIOTIC
IL202134A0 (en) Decontamination systems and methods of use thereof
PL2091724T3 (pl) Uchwyty i sposób obróbki konstrukcji toroidalnych